Trial Profile
A Phase 3 aducanumab secondary prevention trial
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Aducanumab (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 31 Jan 2024 According to a Biogen Media release, company will discontinue the development and commercialization of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use.
- 31 Jan 2024 Status changed from planning to withdrawn prior to enrolment, according to a Biogen Media release.
- 24 Apr 2019 According to a Biogen media release, the company has decided not to initiate this study at this point of time.